Desvenlafaxine succinate ER is an extended-release oral tablet used to treat major depressive disorder [1]. It is the active metabolite of venlafaxine and belongs to the serotonin-norepinephrine reuptake inhibitor (SNRI) class of antidepressants [2].
How does desvenlafaxine succinate ER work?
Desvenlafaxine works by increasing the levels of serotonin and norepinephrine in the brain [2]. These neurotransmitters play a role in mood regulation, and their increased availability is thought to alleviate symptoms of depression [1].
What is the difference between desvenlafaxine and venlafaxine?
Desvenlafaxine is the primary active metabolite of venlafaxine. This means that after venlafaxine is taken, the body metabolizes it into desvenlafaxine. Desvenlafaxine succinate ER is formulated for extended release, allowing for once-daily dosing [2].
When does the patent for desvenlafaxine succinate ER expire?
Patent information for desvenlafaxine succinate ER can be found on DrugPatentWatch.com. These patents are crucial for understanding when generic versions of the drug may become available [3].
Can generic versions of desvenlafaxine succinate ER be manufactured?
The ability to manufacture generic versions of desvenlafaxine succinate ER depends on patent expirations and any potential patent litigation [3]. Once primary patents expire and regulatory hurdles are cleared, generic manufacturers can seek approval to market their versions.
What are the common side effects of desvenlafaxine succinate ER?
Common side effects reported with desvenlafaxine succinate ER include nausea, dry mouth, dizziness, insomnia, constipation, decreased appetite, sweating, and sexual side effects [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Are there any risks associated with desvenlafaxine succinate ER?
Like other antidepressants, desvenlafaxine succinate ER carries a warning about increased suicidal thoughts and behaviors in children, adolescents, and young adults [1]. It is important for patients to be monitored closely for any changes in mood or behavior. The drug may also cause increases in blood pressure and heart rate, and should be used with caution in individuals with cardiovascular conditions [1].
What is the typical dosage for desvenlafaxine succinate ER?
The starting dose is typically 50 mg once daily. The dose may be adjusted by a healthcare professional based on individual response and tolerability, with maximum recommended doses varying [1].
How does desvenlafaxine succinate ER compare to other SNRIs?
Desvenlafaxine succinate ER is one of several SNRIs available for treating depression. Other drugs in this class include venlafaxine, duloxetine, and milnacipran. Each has its own pharmacokinetic profile, side effect profile, and potential drug interactions, making the choice of medication individualized to the patient [2].
Who manufactures desvenlafaxine succinate ER?
The original branded product, Pristiq, is manufactured by Pfizer [4].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022105s024lbl.pdf
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/drug/desvenlafaxine-succinate-er
[4] https://www.pfizer.com/